Dynamic List Information
Dynamic List Data
Study Title
An Open-Label Phase II Trial to Evaluate the Efficacy and Safety of Neoadjuvant Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel Plus Trastuzumab and Pertuzumab in Early Stage HER2-Negative Breast Cancer Patients Selected with a Test Measuring Live Cell HER2 Signaling Transduction (FACT 1)
Sponsor Name
Celcuity
NCT Number
NCT03412643
IDE Number
G160277
CMS Approval Date
2018-10-26
Category
B